Catalio Capital Management

Catalio Capital Management is a venture capital firm based in New York, founded in 2020 by George Petrocheilos and Dr. Jacob Vogelstein. The firm focuses on investing in breakthrough biomedical technology companies, seeking to support innovation in this critical sector. Catalio Capital Management engages in various investment strategies, including private equity, private credit, and public equity, while employing a fundamental, bottoms-up approach to investment analysis. As a Registered Investment Adviser, the firm aims to leverage its expertise to identify and nurture promising companies in the biomedical field, contributing to advancements in healthcare and technology.

Tom V. Brooks

Partner and Member of the Investment Committee

Michael Cheaney

Vice President

Will Denehy

Vice President

Napoleone Ferrara

Venture Partner

Elliot Fishman

Venture Partner

Justin Hanes

Venture Partner

Matthew Hobson Ph.D

Principal

Elie Kobrin

Partner and Head of Equities

Olga Maltseva

Partner and Head of Operations

Scott O'Sullivan

Principal and Head of Trading

George C. Petrocheilos

Co-Founder and Managing Partner

Isaac Ro

Partner

Ben Snedeker

Partner and Co-Head of Public Equities

Rob Snyder

Partner

Solomon H. Snyder

Venture Partner

Kenan Turnacioglu

General Partner

R. Jacob Vogelstein

Managing Partner

Diamantis Xylas MD

Partner and Co-Head of Investments

Joan Brugge Ph.D

Venture Partner

Debora Marks Ph.D

Venture Partner

64 past transactions

Imbria Pharmaceuticals

Series B in 2025
Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.

Character Biosciences

Series B in 2025
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Perceive Pharma

Series A in 2025
Perceive Pharma operates as a pharmaceutical company. Perceive Pharma develops innovative small molecule neuroprotective treatments.

Aviceda Therapeutics

Series C in 2025
Aviceda Therapeutics is a late-stage pre-clinical biotechnology company focused on developing innovative therapies for glyco-immune diseases. The company leverages glycobiology and a proprietary cell-based high-throughput screening platform to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda’s therapeutic pipeline includes a range of products aimed at various conditions, such as dry eye, diabetic retinopathy, retinoblastoma, and other diseases in the fields of oncology, neurology, and fibrosis. The company’s approach combines advanced biological insights with cutting-edge nanoparticle technology, enabling the development of targeted treatments designed to improve patient outcomes.

Alentis Therapeutics

Series D in 2024
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

PrognomIQ

Series D in 2024
PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

Orasis Pharmaceuticals

Series D in 2024
Orasis Pharmaceuticals Ltd is a pharmaceutical company based in Herzliya, Israel, founded in 2015. The company specializes in the development of corrective eye drops aimed at treating presbyopia, a common age-related vision condition. Its primary product, CSF-1, is designed to improve near visual acuity through pupil modulation, thereby alleviating the need for reading glasses. By repurposing existing, well-studied molecules, CSF-1 aims to provide an effective, safe, and easy-to-use solution that enhances the quality of life for individuals affected by presbyopia. This noninvasive treatment option offers patients a practical alternative for managing their near vision difficulties.

Orasis Pharmaceuticals

Venture Round in 2024
Orasis Pharmaceuticals Ltd is a pharmaceutical company based in Herzliya, Israel, founded in 2015. The company specializes in the development of corrective eye drops aimed at treating presbyopia, a common age-related vision condition. Its primary product, CSF-1, is designed to improve near visual acuity through pupil modulation, thereby alleviating the need for reading glasses. By repurposing existing, well-studied molecules, CSF-1 aims to provide an effective, safe, and easy-to-use solution that enhances the quality of life for individuals affected by presbyopia. This noninvasive treatment option offers patients a practical alternative for managing their near vision difficulties.

Superluminal Medicines

Series A in 2024
Superluminal Medicines is a biotechnology company specializing in generative biology and chemistry. It employs a unique platform that combines deep biological and chemical expertise, machine learning, and proprietary big data infrastructure to rapidly generate candidate-ready compounds for drug discovery and development. By integrating high-throughput experimental data with advanced algorithms, the company aims to accelerate the identification and optimization of novel drug candidates, improving efficiency and success rates in small molecule drug development compared to traditional methods.

Noetik

Series A in 2024
Noetik is an AI-native biotechnology company focused on the discovery and development of cancer immunotherapies. Utilizing advanced machine learning techniques, Noetik's platform identifies new therapeutic targets and designs innovative treatments. By harnessing self-supervised learning and integrating diverse human multimodal data, the company aims to enhance the precision and effectiveness of immunotherapies. This approach enables the development of more personalized cancer treatments, contributing to the advancement of targeted therapies in oncology.

Imperative Care

Series E in 2024
Imperative Care, Inc. is a medical technology company based in Campbell, California, established in 2015. The company specializes in developing innovative solutions aimed at enhancing the diagnosis, treatment, and rehabilitation of stroke patients. Its primary offerings include the Large Distal Platform, a catheter designed to facilitate access to treatment sites for both ischemic and hemorrhagic stroke procedures, and the ZOOM Aspiration System, which works in conjunction with the Large Distal Platform to provide a comprehensive solution for clot removal across various occlusion sizes. By focusing on improving the speed and effectiveness of acute stroke treatment, Imperative Care aims to address significant unmet needs in stroke care, ultimately providing patients with better prospects for recovery.

InSightec

Private Equity Round in 2024
InSightec Ltd. is a pioneering company based in Tirat Carmel, Israel, specializing in non-invasive medical treatments through its Exablate platform, which employs MR guided focused ultrasound technology. Founded in 1999, InSightec develops and distributes systems that address various oncology and gynecology conditions, including the Exablate Neuro for personalized thalamotomy in movement disorders and pain management. The Exablate system has received multiple regulatory approvals, including CE marks and FDA approval, for treatments of symptomatic uterine fibroids, pain from bone metastases, and adenomyosis. The company provides comprehensive support services, including onsite clinical training and maintenance, to medical professionals using its technology in facilities across Israel and internationally. InSightec maintains a strategic partnership with Lantheus Holdings and has expanded its presence in Europe, Asia, and the Americas, earning recognition for its innovative contributions to the field of acoustic surgery.

Avava

Venture Round in 2024
Avava is a pioneering company specializing in precision skin therapy aimed at enhancing the quality of life for patients globally. It has developed advanced 3D laser treatment technology that focuses on rejuvenating skin color. This innovative technology specifically addresses conditions such as melasma and post-inflammatory hyperpigmentation, allowing healthcare providers to deliver effective tissue treatments to their patients. Through its commitment to improving skin health, Avava seeks to provide solutions that significantly benefit individuals facing various skin challenges.

PinkDx

Series A in 2024
PinkDx is a biotechnology company specializing in women's health. It develops molecular tests to improve diagnostic outcomes for women with vague gynecological cancer symptoms, offering alternatives to invasive procedures. This enables more comfortable and efficient resolution of health concerns, providing timely and positive impacts on patients' lives.

ARTARA THERAPEUTICS

Post in 2024
ARTARA THERAPEUTICS is a clinical-stage healthcare company focused on developing transformative therapies for individuals with rare and specialty diseases. Its lead program, TARA-002, is an investigational cell therapy designed to treat lymphatic malformations and non-muscle invasive bladder cancer. Additionally, the company is advancing intravenous choline chloride, an investigational phospholipid substrate replacement therapy aimed at addressing intestinal failure-associated liver disease. Based in New York, ARTARA THERAPEUTICS is dedicated to providing innovative solutions for patients with limited treatment options, leveraging a team that values creativity and diverse perspectives to expedite the development of its therapies.

Clasp Therapeutics

Series A in 2024
Clasp Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapeutics. The company has created a platform that aims to enhance the ability of the immune system to recognize and eliminate challenging tumors associated with common driver mutations, irrespective of tumor type. By leveraging precision medicine, Clasp Therapeutics seeks to identify cancer-specific markers that allow for the targeted destruction of tumor cells, thereby improving treatment outcomes for patients with difficult-to-treat cancers.

Roshal Imaging Services

Venture Round in 2024
Roshal Imaging Services is a provider of on-site and portable diagnostic Vascular and General body (Ob/Gyne) ultrasound services. The company was founded in 2005 and is based in Katy, Texas, United States.

NextPoint Therapeutics

Series B in 2024
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

OnCusp Therapeutics

Series A in 2024
OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

Lassen Therapeutics

Series B in 2023
Lassen Therapeutics is a biotechnology company focused on developing monoclonal antibodies as potential treatments for fibrosis, rare diseases, and oncology. Its lead candidate, LASN01, targets the IL-11 receptor alpha, a critical mediator in fibrosis and tumor microenvironment organization. By blocking IL-11, Lassen Therapeutics aims to offer a more effective treatment strategy compared to traditional approaches that focus on other factors, such as TGF-β and CTGF. The company's innovative biotherapeutics leverage advanced antibody technologies to address serious health conditions, ultimately improving the lives of patients suffering from these diseases.

RefleXion Medical

Venture Round in 2023
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Sanguine

Debt Financing in 2023
Sanguine is a company focused on enhancing translational biomedical research by facilitating patient participation. It aims to bridge the gap between patients and researchers by offering personalized medicine solutions and a range of tools and concierge services. Sanguine empowers patients to engage in research from the comfort of their homes while ensuring transparency throughout the research process. The company's approach emphasizes respectful patient support and appropriate compensation, fostering a positive experience for participants and yielding more impactful biospecimens for research. Through its efforts, Sanguine seeks to improve the development of new treatments by actively involving patients in the medical research landscape.

Iambic

Series B in 2023
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Rejuveron Life Sciences

Series B in 2023
Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

Georgiamune

Series A in 2023
Georgiamune is a biotechnology company specializing in immunotherapy for cancer treatment. It develops advanced immunotherapeutic and homeostatic therapies aimed at enhancing the body's natural defenses against cancer, with the goal of improving patient recovery times.

Volastra

Series A in 2023
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

NextPoint Therapeutics

Series B in 2023
NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. It advances therapeutic approaches utilizing the unique upregulation of HHLA2 in cancer as an anchor for tumor-targeting therapeutic modalities.

Spiral Therapeutics

Venture Round in 2023
Spiral Therapeutics, Inc. is a clinical-stage pharmaceutical company founded in 2016 and based in San Francisco, California. The company specializes in developing novel therapies for inner ear disorders, particularly focusing on acute and subacute hearing loss as well as balance disorders caused by neurodegenerative, inflammatory, or vascular issues. Spiral Therapeutics employs a unique platform that aims to deliver targeted drug therapies directly to the inner ear, optimizing treatment effectiveness by ensuring that the right medications are administered at the right location and for the appropriate duration. Through its innovative approach, the company seeks to provide patients with effective treatments for hearing loss and related conditions.

Perceive Biotherapeutics

Series B in 2023
Perceive Biotherapeutics is a biotechnology company focused on developing innovative ophthalmic therapeutics aimed at treating various eye diseases. The company leverages advanced protective biologies to create a diverse pipeline of therapeutic assets that target significant causes of irreversible blindness. By employing multiple therapeutic modalities, Perceive Biotherapeutics aims to provide medical professionals with effective solutions for preventing vision loss and enhancing patient outcomes in the field of ophthalmology.

Ensoma

Series B in 2023
Ensoma is a biotechnology company focused on advancing genomic medicine through its innovative in vivo approach, utilizing proprietary Engenious vectors. These vectors are engineered to deliver a wide array of gene modification technologies directly to blood and immune cells, including T cells, B cells, and myeloid cells, without the necessity for stem cell collection or prior myeloablative conditioning, which can pose risks to patients. This unique method allows for the administration of therapies via a single injection, enhancing accessibility and convenience in various healthcare settings, even where resources may be limited. Ensoma aims to expand the curative potential of genomic medicine, making it more accessible to patients in need.

Metagenomi

Series B in 2023
Metagenomi, Inc. is a genetic medicines company focused on developing innovative gene editing systems to address genetic diseases. Incorporated in 2016 and headquartered in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to discover novel genome editing technologies. By sourcing cellular machinery from previously uncharacterized organisms, the company creates a proprietary toolbox that includes programmable nucleases, base editors, and advanced integration systems like prime editing and CRISPR-associated transposases. These systems are designed to be ultra-small, efficient, and highly specific, minimizing the risk of immune responses. Metagenomi aims to revolutionize gene editing techniques and deliver curative therapeutics to patients worldwide.

Sickbay

Debt Financing in 2022
Sickbay is a healthcare services company that specializes in patient monitoring and analytics. Founded in 1999, Sickbay offers a software platform designed to assist healthcare professionals by providing comprehensive access to patient data, including medical histories and real-time monitoring from various devices. Its solutions focus on automating documentation and improving alarm management, which helps reduce unnecessary alarm noise and ensures that care providers receive pertinent alerts. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, aimed at supporting hospital professionals and medical staff in delivering informed, data-driven patient care.

Haystack Oncology

Series A in 2022
Haystack Oncology is an oncology company that specializes in advanced liquid biopsy diagnostic technology aimed at improving cancer treatment strategies and patient outcomes. The company utilizes state-of-the-art circulating tumor DNA detection methods to enhance the diagnosis of minimal residual disease, allowing for more informed therapy decision-making. By analyzing tumor-specific markers in blood samples, Haystack Oncology's technology provides high sensitivity for early detection of recurrent disease, thereby enabling healthcare teams to effectively manage cancer treatment. The company's innovative approach seeks to transform how cancer is monitored and treated, ultimately benefiting patients through improved diagnostic accuracy and treatment effectiveness.

Proto Axiom

Series A in 2022
Proto Axiom is an incubator based in Melbourne, Australia, established in 2021. The company focuses on enhancing the country's biotechnology sector by fostering the development of innovative drug and medical equipment technologies. Recognizing that Australia produces significant intellectual property in these fields but struggles with downstream commercialization, Proto Axiom aims to retain this valuable intellectual property within the country by developing preclinical expertise and supporting local ventures. Through its initiatives, the firm seeks to create job opportunities and bolster the domestic biotechnology landscape.

Fractyl Health

Series F in 2022
Fractyl Health Inc. is a medical technology company dedicated to developing innovative solutions for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The company specializes in a minimally invasive procedure known as Revita DMR, or duodenal mucosal resurfacing therapy, which rejuvenates the lining of the duodenum through hydrothermal ablation. This approach aims to remove excessive layers of the duodenal mucosa that accumulate due to unhealthy diets, thereby addressing the root causes of metabolic disorders. Founded in 2010 and based in Lexington, Massachusetts, Fractyl Health seeks to redefine the treatment landscape from chronic management to durable, disease-modifying therapies, ultimately enhancing patient health and reducing the burden on healthcare systems.

Cartography Biosciences

Series A in 2022
Cartography Biosciences is a biotechnology company focused on developing cancer therapies through precision medicine. The company aims to revolutionize cancer immunotherapies by identifying the safest and most effective targets for treatment. Utilizing a platform-based cell therapy approach, Cartography employs single-cell analysis to discover novel CAR-T targets. This methodology empowers clients to enhance their molecular biology and computational methods, facilitating the advancement of innovative cancer immunotherapies. By prioritizing precision and safety, Cartography Biosciences is dedicated to transforming the landscape of cancer treatment.

Xilis

Series A in 2022
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Anagenex

Series A in 2022
Anagenex is a seed stage biotechnology company that specializes in drug discovery, focusing on challenging medical targets. The company has developed an innovative platform that significantly accelerates the discovery of small molecule drugs and the identification of pharmaceutical compounds. By utilizing machine learning in conjunction with DNA-encoded libraries, Anagenex's technology can rapidly analyze a vast number of compounds, generating extensive data sets and conducting parallel biochemical experiments. This capability is enhanced by proprietary artificial intelligence models, which facilitate the development of new therapeutic drugs aimed at addressing critical medical needs.

Sickbay

Venture Round in 2022
Sickbay is a healthcare services company that specializes in patient monitoring and analytics. Founded in 1999, Sickbay offers a software platform designed to assist healthcare professionals by providing comprehensive access to patient data, including medical histories and real-time monitoring from various devices. Its solutions focus on automating documentation and improving alarm management, which helps reduce unnecessary alarm noise and ensures that care providers receive pertinent alerts. Additionally, Sickbay engages in the wholesale marketing of FDA-authorized nutritional supplements, aimed at supporting hospital professionals and medical staff in delivering informed, data-driven patient care.

Character Biosciences

Series A in 2022
Character Therapeutics is a patient-driven therapeutics company that uses genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines. Its dedication to patients is reflected in the high standards set to ensure privacy, data security, ethics, scientific rigor, and a meaningful impact on patient health. To enable clinical genomic research, the company collaborates with patients, providers, payers, and scientists to create deeply phenotyped patient cohorts.

Octant Bio

Series B in 2022
Octant Bio is a company focused on developing synthetic technology to enhance health and treat diseases. The firm employs synthetic biology, genome engineering, next-generation sequencing, and computational tools to measure the activity of thousands of receptor pathways in human cells simultaneously. This approach allows scientists to use machine learning methods to engineer small molecules that can interact with multiple receptors, offering new potential for treating complex diseases.

Pheast Therapeutics

Series A in 2022
Pheast Therapeutics is a cancer immunotherapy company established in 2020 and based in Palo Alto, California. The company is dedicated to developing innovative checkpoint therapies aimed at utilizing the innate immune system to combat cancer. Specifically, Pheast Therapeutics focuses on blocking macrophage checkpoints, which enhances the ability of macrophages to effectively eliminate tumors, particularly in ovarian and breast cancers. By targeting these immune checkpoints, Pheast Therapeutics aims to improve patient survival rates in oncology.

Celsius Therapeutics

Series B in 2022
Celsius Therapeutics, Inc. is a biotechnology company focused on developing precision medicines for patients suffering from cancer and autoimmune diseases. Founded in 2018 and based in Cambridge, Massachusetts, the company employs a multidisciplinary approach, integrating the expertise of scientists, computational biologists, and clinicians. Celsius Therapeutics utilizes advanced techniques such as single-cell genomic analysis and machine learning to identify and develop innovative therapeutic solutions. By leveraging these cutting-edge technologies, the company aims to create life-changing medicines that address unmet medical needs.

Affini-T Therapeutics

Venture Round in 2022
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-cell therapies designed to eradicate tumors.

PrognomIQ

Venture Round in 2022
PrognomiQ is a technology company specializing in transforming the early detection and treatment of complex diseases like cancer. It generates comprehensive proteomic, genomic, and metabolomic data to provide insights into these conditions, aiming to enhance patient outcomes. The company's innovative approach involves developing advanced test products that improve understanding and management of health issues by integrating diverse health data types.

RefleXion Medical

Venture Round in 2022
RefleXion Medical Inc. is a medical equipment company based in Hayward, California, focused on revolutionizing cancer treatment through its biologically-guided radiotherapy system (BgRT). This innovative technology allows tumors to continuously signal their location during treatment, enabling the simultaneous targeting of multiple tumors, even in cases of metastasized cancer. The RefleXion X1 machine is cleared for various forms of radiotherapy, including stereotactic body radiotherapy, stereotactic radiosurgery, and intensity-modulated radiotherapy. The BgRT system utilizes positron-emission tomography (PET) imaging data to synchronize tumor location information with the linear accelerator, allowing for real-time adjustments in treatment delivery with subsecond latency. RefleXion Medical has established strategic collaborations with Telix Pharmaceuticals Limited and HealthMyne Inc. since its incorporation in 2009.

Sherlock Biosciences

Series B in 2022
Sherlock Biosciences, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative molecular diagnostic solutions. The company utilizes advanced engineering biology tools, such as CRISPR and synthetic biology, to create diagnostic platforms capable of delivering accurate and rapid results. Its notable technologies include SHERLOCK, a method for detecting and quantifying specific genetic sequences, and INSPECTR, which is designed for versatile, easy-to-use diagnostics. Sherlock Biosciences aims to serve various applications, including precision oncology, infectious disease identification, food safety, at-home testing, and general disease detection. Founded in 2018, the company is committed to providing affordable diagnostics suitable for diverse settings, including those with low-resource environments.

Satellite Bio

Series A in 2022
Satellite Bio is a company dedicated to advancing cell therapy and regenerative medicine through innovative approaches in synthetic biology and tissue engineering. It develops proprietary, off-the-shelf implantable satellite organs, which are designed as living therapeutic solutions aimed at addressing complex diseases. By focusing on creating these advanced cell therapies, Satellite Bio seeks to transform the lives of patients suffering from serious health conditions, offering new hope for effective treatment options.

Septerna

Series A in 2022
Septerna is a biotechnology company focused on the discovery and development of novel small-molecule medicines that target G protein-coupled receptors (GPCRs). The company aims to improve patient outcomes by leveraging advanced drug discovery technologies, including innovative screening methods and structure-based drug design. Septerna utilizes its proprietary Native Complex platform to facilitate industrial-scale drug discovery, enabling researchers to identify effective treatments for a diverse array of diseases. Through its commitment to combining cutting-edge technology with a focus on GPCR targets, Septerna seeks to advance the field of medicine and enhance the quality of life for patients.

DNA Script

Series C in 2022
DNA Script is a pioneering company in the field of DNA synthesis, focused on enhancing life sciences and human health through innovative technology. It has developed the SYNTAX, the world's first benchtop DNA printer, which allows laboratories to produce synthetic oligonucleotides using a novel enzymatic process. This method employs natural enzymes for nucleic acid synthesis, enabling rapid and efficient production of critical genomic experimental precursors. By providing greater control over workflow and accelerating access to results, DNA Script supports researchers in advancing experiments and developing new therapeutics effectively.

Hyperfine

Post in 2021
Hyperfine is a pioneering medical device company known for developing Swoop, the first FDA-cleared point-of-care MRI system. Swoop is designed to enhance patient access to rapid diagnosis and treatment, regardless of socioeconomic factors or geographic location. This innovative portable MRI system operates at a lower magnetic field strength than traditional MRI machines, allowing for high-quality imaging in a variety of clinical environments. Swoop can be easily transported to a patient's bedside, requires only a standard electrical outlet, and is controlled via an iPad, facilitating quick scans that support critical decision-making in settings such as emergency departments and intensive care units. Hyperfine generates revenue through the sale of its MRI devices as well as service sales, which include subscriptions for bundled devices, maintenance, and software.

Iambic

Series A in 2021
Iambic Therapeutics focuses on accelerating molecular discovery through its innovative quantum molecular simulation engine. By integrating artificial intelligence and automated synthetic development, the company aims to enhance the design of small-molecule therapeutics. This technology significantly improves the accuracy of molecular predictions, providing valuable insights for therapeutic discovery. Iambic Therapeutics is committed to transforming the drug development process, enabling physicians to access more precise molecular data and ultimately improving treatment outcomes.

Bayesian Health

Venture Round in 2021
Bayesian Health Inc. is a digital health company headquartered in New York, New York, that specializes in developing an AI-driven platform designed to enhance patient care within hospital settings. The platform integrates with electronic medical records (EMR) systems to provide real-time data and actionable insights, allowing clinical staff and hospital leadership to monitor illness severity and detect changes in patient acuity. By leveraging artificial intelligence and machine learning, Bayesian Health's technology supports healthcare providers in making informed, data-driven decisions, thereby improving the efficiency and safety of patient care. Established in 2016, the company aims to optimize decision-making processes in complex clinical environments, ultimately increasing the capacity of frontline healthcare teams.

Xilis

Series A in 2021
Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Enveda Biosciences

Series A in 2021
Enveda Biosciences is a biotechnology company that employs artificial intelligence-powered tools to investigate and define molecules sourced from living organisms. Its primary objective is to build an exhaustive database of chemical biodiversity, thereby expediting the discovery of novel medicines. The company's innovative drug discovery platform integrates machine learning, metabolomics, and robotics to analyze natural samples for both chemical structure and biological activity, eliminating the need for isolating individual compounds or extensive experimentation. This enables healthcare industry clients to develop a wide range of new medications, from antibiotics to hypotensives.

Volastra

Seed Round in 2021
Volastra Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for metastatic cancers. Established in 2019 and headquartered in New York, the company leverages unique insights into chromosomal instability to create targeted treatment strategies. Volastra utilizes a library of organoids derived from metastatic cancer samples to better understand tumor spread and identify effective therapeutic approaches. Additionally, the company combines artificial intelligence, bioinformatics, and proprietary imaging techniques, which enhance the ability of healthcare professionals to determine which cancers are more likely to metastasize. This approach aims to facilitate quicker target identification, optimize patient selection for therapies, and ultimately improve patient outcomes.

Immunai

Series A in 2021
Immunai Inc. is a biotechnology company that specializes in developing an artificial intelligence-based immune profiling platform aimed at enhancing drug development and improving disease detection, diagnosis, and treatment. The company utilizes single-cell genomics and machine learning algorithms to conduct high-resolution profiling of the immune system, generating valuable biological insights that facilitate research and development. Immunai's platform focuses on biomarker discovery, enabling the identification of how immune cells respond to various conditions, and supports the development of therapies for oncology and autoimmune disorders. Established in 2018 and headquartered in New York City, Immunai also maintains offices in San Francisco and Tel Aviv, collaborating with academic institutions, biopharmaceutical firms, and biotechnology companies to advance its mission of mapping the immune system and its functions.

Cambrian Biopharma

Series B in 2021
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

Paige

Series C in 2021
Paige is a company founded in 2017 by Thomas Fuchs and colleagues from Memorial Sloan Kettering Cancer Center, specializing in computational pathology products aimed at enhancing diagnostic precision and treatment decision-making for cancer patients. The company has developed a platform that employs advanced deep learning algorithms, including convolutional and recurrent neural networks, to enable rapid diagnostic stratification and cancer detection, particularly for breast, prostate, and other major cancer types. This innovative technology is designed to transform the workflow of pathologists, providing them with insights that lead to more accurate diagnoses while minimizing the burden on IT systems and ensuring patient safety and data privacy. Paige is recognized as the first organization to receive FDA breakthrough designation for its computational pathology products.

Sensei Biotherapeutics

Series B in 2021
Sensei Biotherapeutics, Inc. is a clinical-stage biotechnology company based in Gaithersburg, Maryland, with an additional office in Boston, Massachusetts. Founded in 1999, the company specializes in developing precision cancer therapeutics, particularly next-generation immunotherapies. Sensei's proprietary drug discovery platform, ImmunoPhage, focuses on understanding the tumor microenvironment to create novel biologics that target tumor-specific antigens and activate both the innate and adaptive immune systems. The company is working on a range of investigational product candidates, including SNS-101, SNS-102, SNS-103, and SNS-20, which aim to address unmet needs in cancer treatment by selectively disabling immunosuppressive signals or activating immunostimulatory signals within the tumor microenvironment. Through its innovative approach and collaboration with experts in biology, immunology, and oncology, Sensei Biotherapeutics seeks to transform cancer treatment and improve outcomes for patients.

Faze Medicines

Series A in 2020
Faze Medicines is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. It focuses on developing small molecule drugs targeting key drivers of disease pathology, with initial therapeutic areas including amyotrophic lateral sclerosis (ALS) and myotonic dystrophy type 1 (DM1). The company employs advanced screening and proteomics techniques to define condensate interaction networks, aiming to pioneer innovative therapeutics based on biomolecular condensates. Through its research, Faze Medicines seeks to provide effective treatments for complex diseases such as ALS and frontotemporal dementia (FTD).

ATAI Life Sciences

Series C in 2020
ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.

Glympse Bio

Series B in 2020
Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

GlycoEra

GlycoEra is a biotechnology research company focused on developing innovative therapeutics that target significant unmet medical needs in inflammatory and autoimmune diseases, as well as in immune-oncology. The company has established a proprietary platform that enables the creation of first-in-class biologics by assembling customized and highly homogeneous human glycans onto glycoproteins in a site-specific manner. This approach facilitates a deeper understanding of the role of glycans in human health and disease, positioning GlycoEra to contribute meaningfully to the advancement of novel treatment options in the healthcare sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.